X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (232) 232
oncology (208) 208
male (189) 189
female (186) 186
middle aged (182) 182
aged (172) 172
index medicus (164) 164
chemotherapy (153) 153
adult (134) 134
cancer (128) 128
antineoplastic combined chemotherapy protocols - therapeutic use (101) 101
treatment outcome (87) 87
medicine & public health (78) 78
gastric cancer (75) 75
stomach neoplasms - drug therapy (73) 73
fluorouracil (63) 63
metastasis (62) 62
stomach cancer (62) 62
cisplatin (57) 57
colorectal cancer (57) 57
stomach neoplasms - pathology (55) 55
survival (55) 55
surgical oncology (53) 53
care and treatment (52) 52
japan (52) 52
fluorouracil - administration & dosage (51) 51
antineoplastic combined chemotherapy protocols - adverse effects (50) 50
retrospective studies (50) 50
5-fluorouracil (48) 48
cancer research (48) 48
research (47) 47
drug combinations (46) 46
neoplasm staging (45) 45
s-1 (45) 45
survival rate (44) 44
cisplatin - administration & dosage (43) 43
prognosis (42) 42
clinical trials (41) 41
gastroenterology & hepatology (41) 41
oxaliplatin (41) 41
radiotherapy (41) 41
therapy (40) 40
drug administration schedule (39) 39
irinotecan (39) 39
analysis (38) 38
disease-free survival (38) 38
trial (38) 38
colorectal neoplasms - drug therapy (37) 37
oncology, experimental (37) 37
surgery (37) 37
camptothecin - analogs & derivatives (36) 36
chemoradiotherapy (36) 36
aged, 80 and over (35) 35
antineoplastic agents (33) 33
antimitotic agents (32) 32
patients (32) 32
tegafur - administration & dosage (32) 32
antineoplastic agents - therapeutic use (31) 31
esophageal cancer (31) 31
gastroenterology (31) 31
oxonic acid - administration & dosage (31) 31
camptothecin - administration & dosage (30) 30
carcinoma (30) 30
colorectal neoplasms - pathology (30) 30
pharmacology & pharmacy (30) 30
stomach neoplasms - mortality (30) 30
supportive care (30) 30
survival analysis (30) 30
tumors (29) 29
adenocarcinoma - drug therapy (27) 27
combined modality therapy (26) 26
leucovorin (26) 26
antineoplastic combined chemotherapy protocols - administration & dosage (25) 25
cancer patients (25) 25
neoplasm metastasis (25) 25
bevacizumab (24) 24
deoxycytidine - analogs & derivatives (24) 24
antineoplastic agents - adverse effects (23) 23
kaplan-meier estimate (23) 23
pharmacology/toxicology (23) 23
fluorouracil - adverse effects (22) 22
follow-up studies (22) 22
medical colleges (22) 22
capecitabine (21) 21
tegafur - adverse effects (21) 21
abdominal surgery (20) 20
asian continental ancestry group (20) 20
oxonic acid - adverse effects (20) 20
pathology (20) 20
antimetabolites, antineoplastic - therapeutic use (19) 19
antineoplastic agents - administration & dosage (19) 19
cancer therapies (19) 19
combination (19) 19
drug therapy (19) 19
esophageal neoplasms - pathology (19) 19
lymphatic metastasis (19) 19
1st-line treatment (18) 18
adenocarcinoma (18) 18
deoxycytidine - administration & dosage (18) 18
esophageal neoplasms - drug therapy (18) 18
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 10/2014, Volume 25, Issue suppl_5, pp. v18 - v18
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10041, pp. 248 - 257
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2009, Volume 10, Issue 11, pp. 1063 - 1069
Summary Background The best chemotherapy regimen for metastatic gastric cancer is uncertain, but promising findings have been reported with irinotecan plus... 
Hematology, Oncology and Palliative Medicine | SUPPORTIVE CARE | 5-FLUOROURACIL | ONCOLOGY | HIGH-DOSE METHOTREXATE | DOXORUBICIN | ADVANCED ESOPHAGOGASTRIC CANCER | COOPERATIVE GROUP | EUROPEAN-ORGANIZATION | 1ST-LINE THERAPY | III TRIAL | CHEMOTHERAPY | Japan - epidemiology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - secondary | Cisplatin - administration & dosage | Young Adult | Fluorouracil - therapeutic use | Fluorouracil - adverse effects | Time Factors | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Drug Administration Schedule | Risk Assessment | Administration, Oral | Tegafur - adverse effects | Tegafur - therapeutic use | Proportional Hazards Models | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Oxonic Acid - adverse effects | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Oxonic Acid - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Aged | Infusions, Intravenous | Stomach Neoplasms - mortality | Drug Combinations | Adenocarcinoma - mortality | Chemotherapy | Oncology, Experimental | Information services | Research | Metastasis | Stomach cancer | Information services industry | Cancer | Fluorouracil | Index Medicus
Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 4/2015, Volume 20, Issue 2, pp. 207 - 239
Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 2/2018, Volume 23, Issue 1, pp. 1 - 34
Journal Article
Cancer Science, ISSN 1347-9032, 09/2014, Volume 105, Issue 9, pp. 1176 - 1181
This study analyzed outcomes of systemic chemotherapy for advanced neuroendocrine carcinoma ( NEC ) of the digestive system. Clinical data from 258 patients... 
neuroendocrine carcinoma | digestive system | etoposide | irinotecan | Cisplatin | Etoposide | Irinotecan | Digestive system | Neuroendocrine carcinoma | DIAGNOSIS | ETOPOSIDE/CISPLATIN | MANAGEMENT | CELL LUNG-CANCER | PHASE-III TRIAL | CONSENSUS GUIDELINES | IRINOTECAN/CISPLATIN | ONCOLOGY | EXPERIENCE | Leucovorin - administration & dosage | Prognosis | Gastrointestinal Neoplasms - drug therapy | Gastrointestinal Neoplasms - mortality | Humans | Male | Cisplatin - administration & dosage | Gastrointestinal Neoplasms - pathology | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Camptothecin - administration & dosage | Female | Retrospective Studies | Camptothecin - analogs & derivatives | Carcinoma, Neuroendocrine - mortality | Carcinoma, Neuroendocrine - drug therapy | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Neuroendocrine - pathology | Deoxycytidine - analogs & derivatives | Antimitotic agents | Chemotherapy | Carcinoma | Analysis | Gastrointestinal system | Antineoplastic agents | Cancer | Dehydrogenases | Clinical trials | Multivariate analysis | Intestine | Pancreas | Stomach | Medical research | Research & development--R&D | Histology | Gastrointestinal tract | Survival | Patients | L-Lactate dehydrogenase | Esophagus | Medicine | Hospitals | Medical prognosis | Lactic acid | Neuroendocrine tumors | Pharmaceuticals | Original
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 853 - 860
Summary Background Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line... 
Hematology, Oncology and Palliative Medicine | TRIAL | CAPECITABINE | 1ST-LINE TREATMENT | INFUSIONAL FLUOROURACIL/LEUCOVORIN | THERAPY | ONCOLOGY | 5-FLUOROURACIL/FOLINIC ACID | FLUOROPYRIMIDINES | OXALIPLATIN | III NONINFERIORITY | FAILURE | Prodrugs - administration & dosage | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Fluorouracil - analogs & derivatives | Tegafur - adverse effects | Kaplan-Meier Estimate | Oxonic Acid - administration & dosage | Adenocarcinoma - drug therapy | Oxonic Acid - adverse effects | Disease-Free Survival | Prodrugs - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Drug Combinations | Adenocarcinoma - mortality | Medical colleges | Chemotherapy | Oncology, Experimental | Colorectal cancer | Leucovorin | Research | Metastasis | Cancer | Fluorouracil | Analysis
Journal Article